New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
10:31 EDTCHTP, NSR, HZNP, GMCR, OLEDOptions with decreasing implied volatility: CHTP NSR HZNP GMCR OLED
News For CHTP;NSR;HZNP;GMCR;OLED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
08:03 EDTGMCRKeurig receives notification from SEC regarding closing inquiry
Keurig Green Mountain announced it has received notification from the Securities and Exchange Commission that it is closing the previously disclosed four-year inquiry into accounting and disclosure matters at the company and would not be recommending any enforcement action against the company or any of its current or former employees.
07:45 EDTHZNPHorizon Pharma to host conference call
Subscribe for More Information
07:04 EDTHZNPHorizon Pharma acquires U.S. rights to PENNSAID 2% for $45M
Subscribe for More Information
October 15, 2014
06:14 EDTGMCRKeurig Green Mountain implied volatility of 40 at lower end of index mean range
Subscribe for More Information
October 13, 2014
17:06 EDTHZNPHorizon Pharma: Actimmune net sales potential $500M with FDA approval for FA
Subscribe for More Information
07:26 EDTGMCRAB InBev has studied potential deal to acquire PepsiCo, Bloomberg says
Anheuser-Busch InBev (BUD), which has a history of growth via acquisition and has been speculated to be targeting peer SABMiller (SBMRY), has also studied whether a merger with PepsiCo (PEP) makes sense, according to Bloomberg, citing people familiar with the matter. The report added that one source said no talks between Anheuser-Busch and Pepsi are ongoing, no deal is imminent, and the scenario is among many that has been examined. The report also noted that Albert Fried views Monster Beverage (MNST) and Keurig Green Mountain (GMCR) as other suitable targets for AB InBev. Reference Link
05:31 EDTHZNPHorizon Pharma to host analyst day
Analyst Day to be held in King of Prussia, PA on October 13 at 5 pm. Webcast Link
October 9, 2014
15:31 EDTHZNPHorizon Pharma's Actimmune Phase 2 results provide more growth, says Avondale
Avondale said Horizon Pharma's Actimmune Phase 2 results were strong and support incremental annual market opportunity of approximately $300K per year. The firm views the results as another potential growth driver and its Outperform rating and $22 price target.
13:40 EDTHZNPHorizon Pharma presents ACTIMMUNE Phase 2 data
Subscribe for More Information
06:13 EDTGMCRKeurig Green Mountain implied volatility of 34 at lower end of index mean range
October 7, 2014
12:09 EDTGMCROn The Fly: Midday Wrap
Subscribe for More Information
10:02 EDTGMCROn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:25 EDTGMCRKeurig Green Mountain initiated with a Buy at Goldman
Goldman Sachs started shares of Keurig Green Mountain with a Buy rating saying the company is entering a period of accelerating sales and earnings growth. The firm expects growth to be driven by Keurig's Hot system and incremental contribution from the Cold platform. It set a $166 price target for shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use